California State Teachers Retirement System Has $2.29 Million Position in Immunomedics, Inc. (IMMU)

California State Teachers Retirement System cut its stake in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 9.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 163,599 shares of the biopharmaceutical company’s stock after selling 17,490 shares during the period. California State Teachers Retirement System owned approximately 0.11% of Immunomedics worth $2,287,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in IMMU. Amalgamated Bank lifted its holdings in Immunomedics by 8.1% during the second quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 966 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in Immunomedics by 11.4% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 1,473 shares in the last quarter. Legal & General Group Plc lifted its holdings in Immunomedics by 7.4% during the second quarter. Legal & General Group Plc now owns 25,477 shares of the biopharmaceutical company’s stock worth $222,000 after acquiring an additional 1,747 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Immunomedics by 2.3% during the second quarter. The Manufacturers Life Insurance Company now owns 79,520 shares of the biopharmaceutical company’s stock worth $702,000 after acquiring an additional 1,763 shares in the last quarter. Finally, Voya Investment Management LLC lifted its holdings in Immunomedics by 5.9% during the second quarter. Voya Investment Management LLC now owns 50,433 shares of the biopharmaceutical company’s stock worth $445,000 after acquiring an additional 2,808 shares in the last quarter. 76.28% of the stock is owned by institutional investors and hedge funds.

Several research analysts have weighed in on IMMU shares. Jefferies Group lifted their target price on Immunomedics from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, September 19th. Zacks Investment Research upgraded Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Wednesday, October 4th. ValuEngine lowered Immunomedics from a “hold” rating to a “sell” rating in a report on Monday, December 4th. Finally, BidaskClub upgraded Immunomedics from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $15.33.

In other news, insider Behzad Aghazadeh purchased 1,325,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were bought at an average cost of $10.47 per share, for a total transaction of $13,872,750.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Brian A. Markison sold 8,390 shares of the business’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $11.89, for a total value of $99,757.10. Following the completion of the sale, the director now owns 99,178 shares in the company, valued at $1,179,226.42. The disclosure for this sale can be found here. Insiders own 6.60% of the company’s stock.

Shares of Immunomedics, Inc. (NASDAQ:IMMU) opened at $16.51 on Tuesday. The company has a market capitalization of $2,510.00, a PE ratio of -7.37 and a beta of 1.48. Immunomedics, Inc. has a twelve month low of $3.83 and a twelve month high of $17.24. The company has a quick ratio of 0.74, a current ratio of 0.74 and a debt-to-equity ratio of -0.29.

Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.06). sell-side analysts anticipate that Immunomedics, Inc. will post -1.16 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://weekherald.com/2018/01/16/california-state-teachers-retirement-system-has-2-29-million-position-in-immunomedics-inc-immu.html.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply